Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, ...

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

These aren't for the faint of heart.

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...

Recursion Pharmaceuticals (NASDAQ:RXRX) is set to give its latest quarterly earnings report on Wednesday, 2026-02-25. Here's what investors need to know before the announcement. Analysts estimate that ...

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.